DENVER–(BUSINESS WIRE)–Cannabis Science, Inc. (OTCBB:CBIS.ob), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce final negotiations to target an immediate European expansion with opportune acquisitions & licensing deals. This new set of deals is designed to bring to bring new products, revenues, and executive management to the company’s growing operations. The target European company has already created its footprint distributing its products in the European Markets and around the world while meeting Cannabis Science’s standards to ensure the utmost quality control and stringent procedures.
This potential acquisition will give Cannabis Science additional products and revenues along with some outstanding continued growth with a good mix of all three product lines and Cannabis Science formulations in Europe and around the world. Continuing in the current focus with the FDA, OTC markets and dispensaries, the Company expects to expand all its current formulations along with the new European line of products the Company is negotiating to purchase. These new European resources will enhance our internal operations and are a vital piece of fulfilling our business model to bring our full line of both Cannabis Science Brand pharmaceutical and over the counter products to Europe. This acquisition can give Cannabis Science additional resources needed for global distribution channels for their products as well as expanding the market potential for the new European line to be acquired.
Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., stated, “Cannabis Science is very pleased for the opportunity to start a product line in Europe that can expand and open up many doors for our full line of Cannabis Science Brand pharmaceutical and over the counter products. The company will continue to make announcements outlining the outstanding opportunities that will be enhanced by these deals in Europe as information becomes available.”
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Dr. Robert Melamede, President & CEO